Companies: 10,795·Total market cap: $144.5T
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZNASDAQHealthcare● Active
$6.72
$-0.29(-4.14%)
Market Cap$210701528
P/E Ratio—
52W High$50.4
52W Low$6.61
Cash on HandFinancialsRevenue

LENZ Therapeutics, Inc. (LENZ) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

LENZ · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$292.3M▲ +39.9% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$25.2M
cashAndCashEquivalents
Short-Term Investments
$267.2M
shortTermInvestments
YoY Change vs Prior Year
+39.9%
vs prior fiscal year
Latest Quarter
$258.4M
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$292.3MCash on Hand
Total Debt$350,000Total Debt
Net Cash / Net Debt+$292.0MNet Cash Position
Cash vs Debt Ratio
Cash 100%Debt 0%

LENZ Therapeutics, Inc. has a net cash position of $292.0M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$292.3M − $350,000 = +$292.0M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
LENZ annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$292.3M+39.9%
Dec 31, 2024$209.0M+217.7%
Dec 31, 2023$65.8M+48.0%
Dec 31, 2022$44.4M+142.8%
Dec 31, 2021$18.3M-7.6%
LENZ cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.7%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc.YOU
LENZ
$292.3M138.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

LENZ Therapeutics, Inc. (LENZ) cash on hand as of December 31, 2025 is $292.3M, comprising $25.2M in cash and cash equivalents (CCE) plus $267.2M in short-term investments — reported as LENZ Therapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as LENZ Therapeutics, Inc. cash reserves or cash position.

LENZ Therapeutics, Inc. annual cash on hand history shows increased +39.9% in 2025: increased +39.9% in 2025. LENZ Therapeutics, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

LENZ Therapeutics, Inc. carries total debt of $350,000 against cash of $292.3M, resulting in a net cash position of +$292.0M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

LENZ cash on hand · 5 questions

As of December 31, 2025, LENZ Therapeutics, Inc. (LENZ) has $292,347,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $25,179,000 in cash and cash equivalents (CCE) plus $267,168,000 in short-term investments. Latest quarter (March 31, 2026): $258,385,000. Data sourced from the annual 10-K filing via FMP.

LENZ cash on handLENZ cash reservesLENZ cash 2025how much cash does LENZ have

▸ Source: FMP /balance-sheet-statement · US GAAP · LENZ Therapeutics, Inc. · LENZ Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025